Table 1 Characteristics of the study subjects.
From: Serum hepcidin level, iron metabolism and osteoporosis in patients with rheumatoid arthritis
Mean | ± | S.D. | Min | — | Max | |
|---|---|---|---|---|---|---|
Age, years | 67.5 | ± | 11.4 | 22 | — | 92 |
Female, n (%) | 203 | (77.5) | ||||
Body mass index, kg/m2 | 21.9 | ± | 3.4 | 14.4 | — | 33.5 |
Body mass index ≥ 25 kg/m2, n (%) | 46 | (17.6) | ||||
Disease duration, years | 13.6 | ± | 10.6 | 0 | — | 54 |
Rheumatoid factor, U/mL | 121.0 | ± | 256.4 | 0 | — | 2175 |
ESR, mm/h | 19.4 | ± | 17.8 | 0 | — | 110 |
CRP, mg/dL | 0.4 | ± | 0.8 | 0.0 | — | 6.3 |
Matrix metalloprotease 3, mg/mL | 122.4 | ± | 100.0 | 20.0 | — | 836.7 |
DAS28-ESR | 2.6 | ± | 1.0 | 0.5 | — | 6.5 |
DAS28-CRP | 2.2 | ± | 1.5 | 1.0 | — | 20.9 |
SDAI | 6.3 | ± | 6.1 | 0.0 | — | 37.7 |
CDAI | 5.9 | ± | 5.9 | 0.0 | — | 37.4 |
Disease activity (DAS28-CRP), n (%) | high (>4.1), 10 (3.8); moderate (2.7-4.1), 50 (19.1); low (2.3≤, <2.7), 38 (14.5); remission (<2.3), 164 (62.6) | |||||
Disease activity (CDAI), n (%) | high (>22), 6 (2.3); moderate (10<, ≤22), 40 (15.3); low (2.8<, ≤10), 123 (46.9); remission (≤2.8), 93 (35.5) | |||||
HAQ-DI | 0.5 | ± | 0.7 | 0 | — | 3 |
Prednisolone use, n (%) | 195 | (74.4) | ||||
Daily prednisolone dose, mg/day | 3.0 | ± | 3.5 | 0 | — | 25 |
Methotrexate use, n (%) | 138 | (52.7) | ||||
Weekly methotrexate dose, mg/week | 4.0 | ± | 4.3 | 0 | — | 14 |
Biological DMARD use, n (%) | 88 | (33.6) | ||||
Infliximab, n (%) | 24 | (9.2) | ||||
Tocilizumab, n (%) | 21 | (8.0) | ||||
Abatacept, n (%) | 12 | (4.6) | ||||
Etanercept, n (%) | 12 | (4.6) | ||||
Golimumab, n (%) | 8 | (3.1) | ||||
Adalimumab, n (%) | 10 | (3.8) | ||||
Certolizumab pegol, n (%) | 1 | (0.4) | ||||
Serum adjusted calcium, mg/dL | 9.6 | ± | 0.8 | 8.6 | — | 19.6 |
Serum adjusted calcium level, n (%) | high (>10.1), 17 (6.5); normal (8.8-10.1), 239 (91.2); low (<8.8), 6 (2.3) | |||||
Serum phosphate, mg/dL | 3.3 | ± | 0.6 | 1.7 | — | 4.8 |
Serum creatinine, mg/dL | 0.7 | ± | 0.2 | 0.4 | — | 1.7 |
eGFR, mL/min/1.73 m2 | 73.3 | ± | 19.6 | 22.9 | — | 132.3 |
Red blood cell count, 104/mL | 413.0 | ± | 49.4 | 273 | — | 571 |
Hemoglobin, g/dL | 12.5 | ± | 1.4 | 8.9 | — | 17.6 |
High level of hemoglobin (>16.8 for male and >14.8 for female), n (%) | 5 | (0.8) | ||||
Low level of hemoglobin (<13.7 for male and <11.6 for female) n (%) | 92 | (35.1) | ||||
Hematocrit, % | 37.5 | ± | 3.9 | 27.3 | — | 51.3 |
Platelet count, ×104/mL | 22.1 | ± | 6.0 | 6.6 | — | 45.2 |
Low platelet count (<15.8 ×104/mL), n (%) | 30 | (11.5) | ||||
Low platelet count (<10 × 104/mL), n (%) | 2 | (0.8) | ||||
Serum ferritin, ng/mL | 62.5 | ± | 63.6 | 0 | — | 392 |
Serum iron, mg/dL | 73.0 | ± | 34.5 | 9 | — | 200 |
UIBC, mg/dL | 245.6 | ± | 68.5 | 51 | — | 458 |
Femoral T score | −1.5 | ± | 1.0 | −4.8 | — | 1.5 |
Femoral Z score | 0.3 | ± | 1.0 | −2.5 | — | 2.9 |
Classification of femoral T score, n (%) | Osteoporosis, 49 (18.7); osteopenia, 150 (57.3), normal 61 (23.3) | |||||
Lumbar T score | −1.2 | ± | 1.5 | −4.8 | — | 3.8 |
Lumbar Z score | 0.5 | ± | 1.4 | −2.7 | — | 5.2 |
Classification of lumbar T score, n (%) | Osteoporosis, 58 (22.1); osteopenia 96 (36.6); normal 108 (41.2) | |||||
Bone alkaline phosphatase, mg/L | 14.4 | ± | 18.2 | 3.5 | — | 242.0 |
TRACP-5b, mU/dL | 319.2 | ± | 198.5 | 18.5 | — | 1350.0 |
25(OH)D, ng/mL | 16.5 | ± | 6.9 | 3.5 | — | 50.3 |
Hepcidin, ng/mL | 14.3 | ± | 19.7 | 0.0 | — | 102.3 |
FGF 23, pg/mL | 59.3 | ± | 32.9 | 0 | — | 376 |
Bisphosphonate or denosumab use, n (%) | 165 | (63.0) | ||||
Denosumab use, n (%) | 8 | (3.1) | ||||
Teriparatide use, n (%) | 9 | (3.4) | ||||
Calcium preparation use, n (%) | 11 | (4.2) | ||||
Active form of vitamin D preparation use, n (%) | 37 | (14.1) | ||||
Vitamin K2 use, n (%) | 8 | (3.1) | ||||
Iron agent use, n (%) | 9 | (3.4) | ||||
Annual change of femoral T score* | −0.009 | ± | 0.160 | |||
Annual change of lumbar T score* | 0.102 | ± | 0.203 | |||
